Insulin oral - Hubei Huagong Biochemical EngineeringAlternative Names: Shulin
Latest Information Update: 13 Nov 2009
At a glance
- Originator Hubei Huagong Biochemical Engineering
- Class Antihyperglycaemics; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Tyrosine aminotransferase stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 15 Mar 2016 Biomarkers information updated
- 13 Nov 2009 No development reported - Phase-III for Type-1 diabetes mellitus in China (Buccal)
- 13 Nov 2009 No development reported - Phase-III for Type-2 diabetes mellitus in China (Buccal)